AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. TBPH
  4. [Form 4] Theravance Biopharma, Inc. Insider Trading Activity

[Form 4] Theravance Biopharma, Inc. Insider Trading Activity

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Sawaf Aziz, SVP & Chief Financial Officer of Theravance Biopharma (TBPH), reported a disposition of 9,368 ordinary shares on 08/20/2025 at an effective price of $13.39 per share. The filing states these shares were withheld by the issuer to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units, and the withholding was not an open-market sale. After the withholding, Mr. Aziz beneficially owns 355,422 ordinary shares, held directly.

Sawaf Aziz, SVP e Chief Financial Officer di Theravance Biopharma (TBPH), ha comunicato la cessione di 9.368 azioni ordinarie il 20/08/2025 al prezzo effettivo di $13,39 per azione. La dichiarazione precisa che le azioni sono state trattenute dall'emittente per soddisfare obblighi fiscali derivanti dal vesting di restricted stock unit precedentemente assegnate; non si 猫 trattato di una vendita sul mercato aperto. Dopo la trattenuta, il signor Aziz detiene beneficiariamente 355.422 azioni ordinarie, possedute direttamente.

Sawaf Aziz, SVP y Chief Financial Officer de Theravance Biopharma (TBPH), inform贸 la disposici贸n de 9.368 acciones ordinarias el 20/08/2025 a un precio efectivo de $13,39 por acci贸n. La presentaci贸n indica que las acciones fueron retenidas por el emisor para cubrir obligaciones fiscales derivadas del vencimiento de unidades restringidas de acciones otorgadas anteriormente; no fue una venta en el mercado abierto. Tras la retenci贸n, el Sr. Aziz posee de forma beneficiaria 355.422 acciones ordinarias, en propiedad directa.

Theravance Biopharma(TBPH)鞚� SVP 瓴� 斓滉碃鞛毂呾瀯鞛�(CFO)鞚� Sawaf Aziz電� 2025雲� 8鞗� 20鞚检棎 氤错喌欤� 9,368欤茧ゼ 欤茧嫻 $13.39鞚� 鞁ろ毃 臧�瓴╈溂搿� 觳橂秳頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 鞝滌稖 靹滊鞐愲姅 頃措嫻 欤检嫕鞚� 鞚挫爠鞐� 攵�鞐悳 鞝滍暅 欤检嫕 雼渼(RSU)鞚� 頄夓偓(vesting)鞐� 霐半澕 氚滌儩頃� 靹戈笀 鞗愳矞歆曥垬 鞚橂毳� 於╇嫻頃橁赴 鞙勴暣 氚滍枆靷皜 鞗愳矞歆曥垬頃� 瓴冹澊氅�, 瓿店皽鞁滌灔 毵り皝鞚� 鞎勲媹鞐堧嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 鞗愳矞歆曥垬 頉� Aziz 鞌姅 歆侅爲 氤挫湢頃橁碃 鞛堧姅 氤错喌欤� 355,422欤茧ゼ 鞁れ鞝侅溂搿� 靻岇湢頃橁碃 鞛堨姷雼堧嫟.

Sawaf Aziz, SVP et Chief Financial Officer de Theravance Biopharma (TBPH), a d茅clar茅 l'ali茅nation de 9 368 actions ordinaires le 20/08/2025 脿 un prix effectif de 13,39 $ par action. Le d茅p么t indique que ces actions ont 茅t茅 retenues par l'茅metteur pour satisfaire des obligations fiscales li茅es au vesting d'unit茅s d'actions restreintes pr茅c茅demment attribu茅es, et qu'il ne s'est pas agi d'une vente sur le march茅 ouvert. Apr猫s cette retenue, M. Aziz d茅tient 脿 titre b茅n茅ficiaire 355 422 actions ordinaires, d茅tenues directement.

Sawaf Aziz, SVP & Chief Financial Officer von Theravance Biopharma (TBPH), meldete die Ver盲u脽erung von 9.368 Stammaktien am 20.08.2025 zu einem effektiven Preis von $13,39 je Aktie. Die Einreichung besagt, dass die Aktien vom Emittenten einbehalten wurden, um steuerliche Abzugsverpflichtungen aus der Vesting von zuvor gew盲hrten Restricted Stock Units zu erf眉llen; es handelte sich nicht um einen Verkauf am offenen Markt. Nach dem Einbehalt besitzt Herr Aziz wirtschaftlich 355.422 Stammaktien, die er direkt h盲lt.

Positive
  • Insider retains substantial direct ownership: 355,422 ordinary shares remain beneficially owned after the transaction.
  • Withholding executed by issuer, not open-market sale, indicating the disposition was administrative to cover taxes rather than an active sale by the officer.
Negative
  • Reduction in holdings: 9,368 shares were disposed of via withholding, reducing the reporting person\'s stake.
  • Recorded transaction price: the withholding was valued at $13.39 per share, which may reflect recent grant valuation or prevailing share price at vesting.

Insights

TL;DR: Routine tax-withholding reduced insider holdings; no open-market disposition suggests limited market impact.

The report shows a non-market withholding of 9,368 shares to cover taxes tied to RSU vesting at $13.39 per share, leaving 355,422 shares owned directly. Because the transaction was an issuer withholding rather than an open-market sale, this is typically viewed as a mechanical reduction in share count rather than an active insider sell signal. The size of the withholding relative to total holdings is modest and likely immaterial to shareholder control or dilution metrics.

TL;DR: Transaction reflects standard executive compensation mechanics, not governance or compliance concerns.

The Form 4 documents tax-withholding tied to RSU vesting, a common administrative action after equity grants vest. The filing identifies the reporting person as an officer (SVP & CFO) and indicates direct ownership post-transaction. There are no disclosures of additional derivative transactions, agreements, or coordinated sales in this filing, and the withholding was executed by the issuer, which typically aligns with standard equity compensation practices and governance protocols.

Sawaf Aziz, SVP e Chief Financial Officer di Theravance Biopharma (TBPH), ha comunicato la cessione di 9.368 azioni ordinarie il 20/08/2025 al prezzo effettivo di $13,39 per azione. La dichiarazione precisa che le azioni sono state trattenute dall'emittente per soddisfare obblighi fiscali derivanti dal vesting di restricted stock unit precedentemente assegnate; non si 猫 trattato di una vendita sul mercato aperto. Dopo la trattenuta, il signor Aziz detiene beneficiariamente 355.422 azioni ordinarie, possedute direttamente.

Sawaf Aziz, SVP y Chief Financial Officer de Theravance Biopharma (TBPH), inform贸 la disposici贸n de 9.368 acciones ordinarias el 20/08/2025 a un precio efectivo de $13,39 por acci贸n. La presentaci贸n indica que las acciones fueron retenidas por el emisor para cubrir obligaciones fiscales derivadas del vencimiento de unidades restringidas de acciones otorgadas anteriormente; no fue una venta en el mercado abierto. Tras la retenci贸n, el Sr. Aziz posee de forma beneficiaria 355.422 acciones ordinarias, en propiedad directa.

Theravance Biopharma(TBPH)鞚� SVP 瓴� 斓滉碃鞛毂呾瀯鞛�(CFO)鞚� Sawaf Aziz電� 2025雲� 8鞗� 20鞚检棎 氤错喌欤� 9,368欤茧ゼ 欤茧嫻 $13.39鞚� 鞁ろ毃 臧�瓴╈溂搿� 觳橂秳頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 鞝滌稖 靹滊鞐愲姅 頃措嫻 欤检嫕鞚� 鞚挫爠鞐� 攵�鞐悳 鞝滍暅 欤检嫕 雼渼(RSU)鞚� 頄夓偓(vesting)鞐� 霐半澕 氚滌儩頃� 靹戈笀 鞗愳矞歆曥垬 鞚橂毳� 於╇嫻頃橁赴 鞙勴暣 氚滍枆靷皜 鞗愳矞歆曥垬頃� 瓴冹澊氅�, 瓿店皽鞁滌灔 毵り皝鞚� 鞎勲媹鞐堧嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 鞗愳矞歆曥垬 頉� Aziz 鞌姅 歆侅爲 氤挫湢頃橁碃 鞛堧姅 氤错喌欤� 355,422欤茧ゼ 鞁れ鞝侅溂搿� 靻岇湢頃橁碃 鞛堨姷雼堧嫟.

Sawaf Aziz, SVP et Chief Financial Officer de Theravance Biopharma (TBPH), a d茅clar茅 l'ali茅nation de 9 368 actions ordinaires le 20/08/2025 脿 un prix effectif de 13,39 $ par action. Le d茅p么t indique que ces actions ont 茅t茅 retenues par l'茅metteur pour satisfaire des obligations fiscales li茅es au vesting d'unit茅s d'actions restreintes pr茅c茅demment attribu茅es, et qu'il ne s'est pas agi d'une vente sur le march茅 ouvert. Apr猫s cette retenue, M. Aziz d茅tient 脿 titre b茅n茅ficiaire 355 422 actions ordinaires, d茅tenues directement.

Sawaf Aziz, SVP & Chief Financial Officer von Theravance Biopharma (TBPH), meldete die Ver盲u脽erung von 9.368 Stammaktien am 20.08.2025 zu einem effektiven Preis von $13,39 je Aktie. Die Einreichung besagt, dass die Aktien vom Emittenten einbehalten wurden, um steuerliche Abzugsverpflichtungen aus der Vesting von zuvor gew盲hrten Restricted Stock Units zu erf眉llen; es handelte sich nicht um einen Verkauf am offenen Markt. Nach dem Einbehalt besitzt Herr Aziz wirtschaftlich 355.422 Stammaktien, die er direkt h盲lt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Sawaf Aziz
(Last) (First) (Middle)
C/O THERAVANCE BIOPHARMA US, LLC
901 GATEWAY BLVD
(Street)
SOUTH SAN FRANCISCO CA 94080
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Theravance Biopharma, Inc. [ TBPH ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP & CHIEF FINANCIAL OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
08/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares 08/20/2025 F 9,368(1) D $13.39 355,422 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.
/s/ Brett A. Grimaud, Attorney-in-Fact 08/22/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What transaction did TBPH insider Sawaf Aziz report on Form 4?

The Form 4 reports a disposition of 9,368 ordinary shares on 08/20/2025 due to share withholding for tax obligations from RSU vesting.

Was the 9,368-share disposition by TBPH an open-market sale?

No. The filing states the shares were withheld by the issuer to satisfy tax obligations and did not involve an open-market transaction.

How many TBPH shares does Sawaf Aziz own after the transaction?

After the withholding, the reporting person beneficially owns 355,422 ordinary shares held directly.

What was the per-share price recorded for the withheld TBPH shares?

The transaction is reported with a price of $13.39 per share for the withheld shares.

What is the reporting person\\'s role at Theravance Biopharma?

The reporting person is identified as SVP & Chief Financial Officer of Theravance Biopharma.
Stock TBPH logo
Theravance Bioph

NASDAQ:TBPH

TBPH Rankings

#2977 Ranked by Market Cap
N/A Ranked by Dividends

TBPH Latest News

Aug 25, 2025
Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy
Aug 12, 2025
Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Jul 28, 2025
Theravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025
Jul 23, 2025
Theravance Biopharma to Participate in an Upcoming Investor Conference
Jun 26, 2025
Theravance Biopharma Announces Approval of YUPELRI庐 (revefenacin) by China's NMPA

TBPH Latest SEC Filings

Aug 25, 2025
[8-K] Theravance Biopharma, Inc. Reports Material Event
Aug 22, 2025
[Form 4] Theravance Biopharma, Inc. Insider Trading Activity
Aug 22, 2025
[Form 4] Theravance Biopharma, Inc. Insider Trading Activity
Aug 22, 2025
[Form 4] Theravance Biopharma, Inc. Insider Trading Activity
Aug 22, 2025
[Form 4] Theravance Biopharma, Inc. Insider Trading Activity

TBPH Stock Data

674.34M
48.06M
4.45%
92.05%
8.25%
Biotechnology
Pharmaceutical Preparations
United States
GEORGE TOWN, GRAND CAYMAN